Daniela Sanchez Basseres

• Abstract

  The most common genetic abnormalities found in lung cancer are activating mutations in the KRAS oncogene. Even though these mutations have been causally linked to the oncogenic process, therapies targeted to oncogenic RAS have sofar failed. Therefore, in order to select better targets for lung cancer therapy, one will need to identify key cancer-relevant KRAS downstream pathways involved …

  EXPLORING IKKbeta KINASE AS AN ANTI-METASTATIC THERAPEUTIC TARGET IN KRAS-INDUCED LUNG CANCER, AP.R
• Identification of a new human gene that codes for a potential cytoskeletal protein belonging to a new subfamily of rho-gap proteins, AR.EXT

• Abstract

  Lung cancer induced by oncogenic mutations of the KRAS GTPase is a very frequent disease, for which there are currently no effective therapies. Although these mutations are closely linked to oncogenesis, different approaches to inhibit RAS proteins directly have previously failed. Therefore, for better therapeutic targets for lung cancer to become available, it is necessary to identify th…

  Exploring IKKbeta kinase as a therapeutic target for lung tumour-initiating cells induced by the KRAS oncogene, BP.MS

• Abstract

  Activating mutations in KRAS are very frequent in Pancreatic Ductal Adenocarcinomas (PDACs), but different approaches to directly target Ras for therapy failed in clinical trials. An alternative route for blocking RAS-driven oncogenic pathways is to target downstream effectors of RAS involved in promoting the oncogenic phenotype. Long non-coding RNAs (lncRNAs) regulate gene expression thr…

  Identification of long non coding RNAs regulated by oncogenic KRAS in pancretic cancer, BP.DD

• Abstract

  Lung cancer is the leading cause of cancer deaths worldwide. The most frequent genetic changes found in lung cancer are driver mutations in the KRAS proto-oncogene. Even though KRAS mutations have been causally linked to the oncogenic process, therapies targeted to oncogenic RAS have failed in clinical trials. Therefore, in order to select better targets for lung cancer therapy, it will b…

  Exploring IKKbeta as an anti-metastatic therapeutic target in KRAS-induced lung câncer, BP.MS

(Only some records are available in English at this moment)

• Abstract

  Lung cancer induced by oncogenic mutations of the KRAS GTPase is a very frequent disease, for which there are currently no effective therapies. Although these mutations are closely linked to oncogenesis, small molecules to inhibit RAS proteins effectively in the clinic still do not exist. Therefore, for better therapeutic targets for lung cancer to become available, it is necessary to ide…

  Investigating the role of IKKbeta kinase and ERBB in the maintenance of the cancer stem-like phenotype in KRAS-driven lung cancer, BE.EP.MS